HIV Clinical Trials in Atlanta, Georgia

6 studies are recruiting for hiv in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies

   This phase 1 study will evaluate the safety, tolerability, and immune responses of two experimental mRNA HIV vaccines in adults living with HIV who are in overall good health. The study will enroll about 42 participants at multiple study sites. Researchers will assess whether these vaccines can sta…

   Stage

   Phase 1

   Ages

   18 to 60

   Site

   The Ponce de Leon Center CRS (Site ID: 5802), Atlanta, Georgia

   Locations

   16 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT07569029 on ClinicalTrials.gov

2. Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver)

   This research is being done to better understand opportunistic infections and cancer in transplant recipients with HIV who receive livers from a donor with HIV compared to livers from donors without HIV.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Emory University, Atlanta, Georgia

   Locations

   19 in total

   Run by

   Johns Hopkins University

   See if you can join NCT07665372 on ClinicalTrials.gov

3. A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1

   This study is testing a lab-made antibody called ePGT121v1-LS that targets a specific part of HIV. Researchers will give it by vein (IV) and under the skin (SC), both on its own and together with two other antibodies, VRC07-523LS and PGDM1400LS, which target different parts of the virus. They will …

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   The Ponce de Leon Center CRS (Site ID: 5802), Atlanta, Georgia

   Locations

   11 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT07390955 on ClinicalTrials.gov

4. Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV

   This is a phase 1, multicenter, open-label, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of DV201P-RNA and DV202B1-RNA, immunogens designed to induce HIV-1 envelope (Env) V2 apex-specific broadly neutralizing antibodies (V2 apex bnAbs). Both vaccines consist…

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   The Ponce de Leon Center CRS (Site ID 5802), Atlanta, Georgia

   Locations

   7 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT07390474 on ClinicalTrials.gov

5. Inflammation and Depression in People With HIV

   The purpose of this 10-week, double-blind, placebo-controlled study is to determine whether inflammation impacts reward and motor neural circuitry to contribute to depressive symptoms like anhedonia and psychomotor slowing in people with Human Immunodeficiency Virus (HIV) and depression. Sixty male…

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Grady Memorial Hospital, Atlanta, Georgia

   Locations

   2 in total

   Run by

   Emory University

   See if you can join NCT05849038 on ClinicalTrials.gov

6. Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health

   This is a partially randomized, open-label phase 1 study to evaluate the safety and immunogenicity of a priming regimen of 426c.Mod.Core-C4b adjuvanted with 3M-052 AF + Alum followed by boosts with HxB2.WT.Core-C4b adjuvanted with 3M-052 AF + Alum. The primary hypothesis is that the boosting with H…

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   Ponce de Leon Center CRS, Atlanta, Georgia

   Locations

   6 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT06796686 on ClinicalTrials.gov